PainChek receives $1.123 million R&D tax incentive refund
Open PDF
| Stock | Painchek Ltd (PCK.ASX) |
|---|---|
| Release Time | 22 Jul 2026, 8:29 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
PainChek receives $1.123 million R&D tax incentive refund
Key Points
- $1.123 million R&D tax incentive refund received
- Strengthens cash position and supports product development
- Includes development of PainChek Adult and Infant algorithms
- Supports US market entry and expansion for children
Full Summary
PainChek Ltd, developer of the world's first AI-powered pain assessment and monitoring application, has announced the receipt of a $1.123 million research and development (R&D) tax incentive refund for the 2025 financial year. This refund, provided by the Australian Government's R&D Tax Incentive program, relates to eligible R&D activities undertaken by PainChek, including the development of its Adult and Infant algorithms and validation activities supporting its entry into the US market and the expansion of its technology for use in children.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In